FDA to review Regeneron's VEGF Trap-Eye

FDA accepted for filing and granted Priority Review to a BLA from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) for VEGF Trap-Eye to treat wet age-related macular degeneration (AMD). The PDUFA date is ...